BT Catalyst

View more issues: May-June 2005, July-August 2005, Jan-Feb 2007

Articles in Sept-Oct 2005 issue of BT Catalyst

• GlaxoSmithKline of Research Triangle Park has agreed to acquire flu vaccine company ID Biomedical of Vancouver
• Adherex Technologies of Durham has closed on a previously announced $8.5 million private placement
• Cognosci of Research Triangle Park received a $286,564 SBIR grant from the National Heart, Lung and Blood Institute for the project
• Institute for Science Learning
• Five questions for Anne Wein
• Arysta to relocate from California
• Icoria of Research Triangle Park will be acquired by Clinical Data of Newton, Mass., in an all-stock transaction valued at about $12.5 million
• The Aurora Funds
• Embrex
• Novozymes North America
• Christopher H. Price, Ph.D., has resigned as CEO of Nobex Corp. of Research Triangle Park to become executive director of the Piedmont Triad Research Park in Winston-Salem
• Voyager seeks $129 million in IPO
• Lantibio of Chapel Hill and Apotex Fermentation of Winnipeg, Canada, have signed an agreement for the development and supply of Lantibio's lead compound
• Biolex Therapeutics of Pittsboro has raised $36 million in a Series B financing led by Polaris Venture Partners and including existing investors Intersouth Partners of Durham, Quaker BioVentures
• Forsyth Technical Community College in Winston-Salem received a $72,776 Regional Development Grant from the North Carolina Biotechnology Center for the project "From Student to Workforce
• Forsyth Technical Community College
• PPD
• North Carolina rated one of least expensive states
• Legislature increases bioscience spending
  by Sam Taylor
• LipoScience of Raleigh has entered into a multi-year agreement with LabCorp of Burlington to offer its proprietary NMR LipoProfile® blood test, which uses nuclear magnetic resonance spectroscopy to measure the number of atherogenic LDL particles that
• Regado Biosciences of Research Triangle Park has completed a $20 million Series B financing co-led by Domain Associates of Princeton, N.J., and Quaker BioVentures of Philadelphia
• Hyperbranch Medical Technology of Raleigh received a $245,060 grant from the National Institute of Biomedical Imaging and Bioengineering
• Three North Carolinians are on the list of the "100 Most Inspiring People in the Life Sciences Industry" as judged by the readers of PharmaVOICE magazine
• Constella Group
• Biotech Forum dates, topics set
• $700 million biotech campus envisioned for Kannapolis
• Metabolon of Research Triangle Park has signed a contract with the National Institute of Mental Health to identify biomarkers occurring in women affected by premenstrual dysphoric disorder
• Research Triangle Regional Partnership
• MRPath of Durham received a $1,105,751 SBIR grant from the National Cancer Institute for part four of the multi-year project "Web-based Phenotyping
• Council for Entrepreneurial Development
• Inspire Pharmaceuticals
• New Biotechnology Center offices to serve Eastern N.C
• Nobex of Research Triangle Park has signed an agreement with Biocon of India for the global co-development of an oral brain-type natriuretic peptide
• Advanced Liquid Logic of Research Triangle Park received $74,538 from the North Carolina Biotechnology Center's SBIR Bridge Loan Award Program
• RTI International of Research Triangle Park was awarded two bioinformatics contracts worth $5.6 million from the National Institutes of Health's National Cancer Institute
• The Aurora Funds
• Quintiles Transnational
• Cheryl McMurry named director of Western Office
• Paradigm Array Labs, the gene expression profiling service unit of Icoria of Research Triangle Park, has signed three unrelated contracts that are expected to generate up to $1.1 million in revenue
• AlphaVax of Research Triangle Park, $351,891 grant from the National Institute of Allergy and Infectious Diseases for part four of a five-year project
• RTI International of Research Triangle Park received a $649,807 SBIR grant
• PPD
• Deadline nears for BIO 2006 Pavilion sponsorship
• BioDelivery Sciences International of Morrisville has entered into a clinical development and license agreement with Clinical Development Capital of Princeton, N.J
• PPD of Wilmington has sold to Takeda Pharmaceutical Co. of Osaka, Japan, the development and marketing rights to dipeptidyl peptidase IV inhibitors being tested for the treatment of type 2 diabetes, for $15 million plus future sums based on sales milesto
• Attagene of Chapel Hill, $1,481,208 grant from the National Institute of Allergy and Infectious Diseases for part two of a five-year project
• Salem College of Winston-Salem received a $36,861 Regional Development Grant from the North Carolina Biotechnology Center to support undergraduate internships and class projects
• Tranzyme Pharma
• GSK, Biolex expand manufacturing plants; Arysta to move from California; Voyager plans IPO
• Biolex Therapeutics of Pittsboro has acquired LemnaGene S.A., a privately held start-up biotechnology company in Lyon, France
• Sicel Technologies of Raleigh has signed a strategic collaboration agreement with CMS of St. Louis
• Breathquant Medical Systems of Charlotte received a $536,828 SBIR grant from the National Heart, Lung and Blood Institute
• Skin Science Institute of Durham received $409,224 from the National Institute of Arthritis and Musculoskeletal and Skin Diseases for part two of a five-year project
• KBI BioPharma
• Biolex expands in Pittsboro, seeks more space
• Diosynth Biotechnology of Research Triangle Park has signed a contract with Agenix of Brisbane, Australia, for process development and manufacture of ThromboView® for Phase III clinical trials and commercial sale
• TriPath Imaging of Burlington has awarded Medical Solutions, its licensed distributor in the United Kingdom, an exclusive five-year contract to supply the SurePath™ liquid-based Pap test to the Greater Lincolnshire Primary Care Trusts
• Bruce Technologies of Chapel Hill received a $364,693 SBIR grant from the National Institute of Biomedical Imaging and Bioengineering
• Zen-Bio of Research Triangle Park received a 24-month $961,578 Phase II SBIR grant from the National Institutes of Health
• Dave Krasnow, a partner in the Intellectual Property Department of KBI BioPharma in Raleigh, has returned to the law firm's Raleigh office from Atlanta
• Business Development Group changes name, expands reach